The FDA's agreement on a streamlined path to approval based on a single Phase 3 trial significantly de-risks the development pathway for nebokitug. Traders should monitor upcoming Phase 3 initiation, partnership developments, and clinical event accrual. The strong biomarker data and regulatory designations (Orphan Drug, Fast Track) increase the likelihood of commercial success if Phase 3 confirms clinical benefit.
Price Chart
Executive Summary
Chemomab Therapeutics reported its full-year and Q4 2025 financial results, highlighted by a successful FDA End-of-Phase 2 meeting for nebokitug in primary sclerosing cholangitis (PSC), alignment on a single Phase 3 trial for potential approval, and strong clinical data presentations. The company has $10.4M in cash, sufficient to fund operations into Q1 2027, while R&D expenses declined due to completion of its Phase 2 trial.
Key Financial Metrics
Key Facts
- FDA aligned with Chemomab on a single Phase 3 trial as a potential path to full approval for nebokitug in PSC, with a clinical event-driven primary endpoint.
- Phase 2 SPRING trial data published in peer-reviewed journals and presented at major liver disease conferences, including AASLD and DDW, with multiple 'posters of distinction' and a Best Oral Presentation award.
- Cash position was $10.4 million as of December 31, 2025, down from $14.3 million in 2024, but provides runway into Q1 2027.
- R&D expenses decreased to $5.8M in 2025 from $11.3M in 2024 due to completion of the Phase 2 trial.
- Net loss narrowed to $9.0M in 2025 from $13.9M in 2024.
- Shares outstanding increased to 575.4M from 377.1M due to financing activities, reflecting a reverse ADS split from 1:20 to 1:80 effective August 2025.
Financial Impact
Reduced R&D spend by $5.5M YoY and narrowed net loss by $4.9M, while maintaining sufficient cash runway into 2027 despite lower cash balance.
Risk Factors
- High reliance on a single asset (nebokitug) and indication (PSC), with no approved products yet.
- Future financing needs likely beyond Q1 2027, which could lead to dilution.
- Forward-looking statements highlight risks around FDA approval, clinical trial execution, manufacturing, and geopolitical exposure in Israel.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258911 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | 6-K | $2.09 $2.80 | ▲ +33.97% | ▲ +35.92% | $1.30 (−37.80%) |
Aug 19, 2026 6w ago | Press Release | $2.09 $2.80 | ▼ −33.97% | ▼ −35.92% | $1.30 (+37.80%) |
Jul 8, 2026 12w ago | 6-K | $1.97 $1.75 | ▼ −11.17% | ▼ −14.44% | $1.30 (−34.01%) |
Jun 2, 2026 17w ago | 6-K | $1.72 $2.27 | ▲ +31.98% | ▲ +32.98% | $1.30 (−24.42%) |
May 14, 2026 20w ago | 6-K | $1.70 $1.65 | ▼ −2.94% | ▼ −2.08% | $1.30 (−23.53%) |
May 14, 2026 20w ago | Press Release | $1.70 $1.65 | ▼ −2.94% | ▼ −2.08% | $1.30 (−23.53%) |
May 6, 2026 21w ago | 6-K | $1.74 $1.72 | ▼ −1.15% | ▼ −4.29% | $1.30 (−25.29%) |
Mar 19, 2026 28w ago | Press Release | $1.93 $1.67 | ▼ −13.47% | ▼ −21.09% | $1.30 (−32.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access